These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37959236)

  • 1. Serum KL-6 as a Candidate Predictor of Outcome in Patients with SARS-CoV-2 Pneumonia.
    Kattner S; Sutharsan S; Berger MM; Limmer A; Jehn LB; Herbstreit F; Brenner T; Taube C; Bonella F
    J Clin Med; 2023 Oct; 12(21):. PubMed ID: 37959236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of serum Krebs von den Lungen-6 (KL-6) levels in COVID-19 pneumonia.
    Letellier A; Rolland-Debord C; Luque-Paz D; Milon A; Choinier P; Blin E; Halitim P; Bravais J; Lefèvre G; Parrot A; Piéroni L; Cadranel J
    Respir Med Res; 2023 Nov; 84():101054. PubMed ID: 37897878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II.
    d'Alessandro M; Bergantini L; Cavallaro D; Gangi S; Cameli P; Conticini E; Siena Covid Unit ; Frediani B; Dotta F; Bargagli E
    Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Krebs von den Lungen-6 levels are associated with mortality and severity in patients with coronavirus disease 2019.
    Yamaya T; Hagiwara E; Baba T; Kitayama T; Murohashi K; Higa K; Sato Y; Otoshi R; Tabata E; Shintani R; Okabayashi H; Ikeda S; Niwa T; Nakazawa A; Oda T; Okuda R; Sekine A; Kitamura H; Komatsu S; Ogura T
    Respir Investig; 2021 Sep; 59(5):596-601. PubMed ID: 33965361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of serum Krebs von den Lungen-6 and chest CT as potential prognostic factors in severe acute respiratory syndrome SARS-CoV-2: a preliminary experience.
    Anastasi E; Manganaro L; Guiducci E; Ciaglia S; Dolciami M; Spagnoli A; Alessandri F; Angeloni A; Vestri A; Catalano C; Ricci P
    Radiol Med; 2022 Jul; 127(7):725-732. PubMed ID: 35704156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum KL-6 Could Represent a Reliable Indicator of Unfavourable Outcome in Patients with COVID-19 Pneumonia.
    Scotto R; Pinchera B; Perna F; Atripaldi L; Giaccone A; Sequino D; Zappulo E; Sardanelli A; Schiano Moriello N; Stanziola A; Bocchino M; Gentile I; Sanduzzi A
    Int J Environ Res Public Health; 2021 Feb; 18(4):. PubMed ID: 33672761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapidly progressive organizing pneumonia associated with COVID-19.
    Horii H; Kamada K; Nakakubo S; Yamashita Y; Nakamura J; Nasuhara Y; Konno S
    Respir Med Case Rep; 2020; 31():101295. PubMed ID: 33224726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of serum Krebs von den Lungen-6 levels in patients with coronavirus disease 2019.
    Chen H; Qin R; Huang Z; Luo W; Zheng P; Huang H; Hu H; Wang H; Sun B
    Cytokine; 2021 Dec; 148():155513. PubMed ID: 34507246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction Value of KREBS Von Den Lungen-6 (KL-6) Biomarker in COVID-19 Patients: A Systematic Review and Meta-Analysis.
    Matuszewski M; Szarpak L; Rafique Z; Peacock FW; Pruc M; Szwed P; Chirico F; Navolokina A; Ladny JR; Denegri A
    J Clin Med; 2022 Nov; 11(21):. PubMed ID: 36362828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploration and correlation analysis of changes in Krebs von den Lungen-6 levels in COVID-19 patients with different types in China.
    Xue M; Zheng P; Bian X; Huang Z; Huang H; Zeng Y; Hu H; Liu X; Zhou L; Sun B; Wu JL; Zhong N
    Biosci Trends; 2020 Sep; 14(4):290-296. PubMed ID: 32565512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the Role of Krebs von den Lungen-6 in Severe to Critical COVID-19 Patients.
    D'Agnano V; Scialò F; Perna F; Atripaldi L; Sanduzzi S; Allocca V; Vitale M; Pastore L; Bianco A; Perrotta F
    Life (Basel); 2022 Jul; 12(8):. PubMed ID: 36013321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of Krebs von den Lungen-6 and fibronectin with pulmonary fibrosis in coronavirus disease 2019.
    Peng DH; Luo Y; Huang LJ; Liao FL; Liu YY; Tang P; Hu HN; Chen W
    Clin Chim Acta; 2021 Jun; 517():48-53. PubMed ID: 33631198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
    Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
    Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum KL-6 level is a useful biomarker for evaluating the severity of coronavirus disease 2019.
    Awano N; Inomata M; Kuse N; Tone M; Takada K; Muto Y; Fujimoto K; Akagi Y; Mawatari M; Ueda A; Izumo T
    Respir Investig; 2020 Nov; 58(6):440-447. PubMed ID: 32863199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analyses.
    Naderi N; Rahimzadeh M
    Virology; 2022 Jan; 566():106-113. PubMed ID: 34896901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential of Krebs von den Lungen-6 as a predictor of relapse in interstitial pneumonia with anti-aminoacyl tRNA synthetase antibodies-positive dermatomyositis.
    Isoda K; Kotani T; Takeuchi T; Konma J; Ishida T; Hata K; Otani K; Fujiwara H; Shoda T; Makino S; Arawaka S
    Clin Respir J; 2018 Jul; 12(7):2235-2241. PubMed ID: 29633527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.